Diabetes drug shows promise in protecting kidneys
en-GBde-DEes-ESfr-FR

Diabetes drug shows promise in protecting kidneys

18/11/2024 Osaka Metropolitan University
Type 2 diabetes can lead to diabetic kidney disease, but a class of drugs that cause the kidneys to remove glucose through urine has been gaining attention. An Osaka Metropolitan University-led research group has investigated how such drugs maintain kidney health.

Known as SGLT2 (sodium-glucose cotransporter-2) inhibitors, the drugs are used to treat type 2 diabetes along with an exercise and diet regimen. The group led by Graduate School of Medicine Associate Professor Katsuhito Mori focused on the SGLT2 inhibitor canagliflozin and its effects on the kidney.

Using BOLD (blood oxygenation level-dependent) MRI, a method used to see changes in blood oxygen flow in the brain to monitor activity, the group found that patients on canagliflozin for five days showed more oxygen in their kidneys the first day after administration of the drug. The researchers believe this indicates that SGLT2 inhibitors might improve the oxygenation of the kidneys, thereby protecting the organs.

“In animal experiments, the amount of oxygen in the kidneys can be measured by inserting a microelectrode, but this is not possible in humans,” Professor Mori explained. “BOLD MRI can measure kidney oxygenation non-invasively, and this is expected to become an important technology for elucidating the mechanisms of kidney disease for the development of therapeutic drugs.”

The findings were published in Frontiers in Endocrinology.

Funding
This study was supported by Mitsubishi Tanabe Pharma Corporation.

Conflict of interest
KM has received speaker fees from Mitsubishi Tanabe Pharma Corporation, Daiichi Sankyo Co., Nippon Boehringer Ingelheim Co., Eli Lilly Japan K.K., AstraZeneca K.K., Ono Pharmaceutical Co. Ltd., Novo Nordisk Pharma Ltd., Kyowa Kirin Co. Ltd., and Mochida Pharmaceutical Co. Ltd., and unrestricted research grants from Chugai Pharmaceutical Co. Ltd, Kyowa Kirin Co. Ltd., Torii Pharmaceutical Co. Ltd., and Sumitomo Pharma Co. Ltd., and research funding from Kyowa Kirin Co. Ltd. TI has received speaker fees from Mitsubishi Tanabe Pharma Corporation, Daiichi Sankyo Co., Nippon Boehringer Ingelheim Co., Eli Lilly Japan K.K., AstraZeneca K.K., Ono Pharmaceutical Co. Ltd., Novo Nordisk Pharma Ltd., Kyowa Kirin Co. Ltd., Mochida Pharmaceutical Co. Ltd., Torii Pharmaceutical Co. Ltd., Otsuka Pharmaceutical Co., Ltd., Sanwa Kagaku Kenkyusho CO., LTD., and Bayer Yakuhin, Ltd., and unrestricted research grant from Eli Lilly Japan K.K. HU has received speaker fees from Mitsubishi Tanabe Pharma Corporation, Daiichi Sankyo Co., Kyowa Kirin, and Mochida Pharmaceutical Co., Ltd. SN has received speaker fees from AstraZeneca K.K., Ono Pharmaceutical Co. Ltd., Otsuka Pharmaceutical Co., Ltd., Novartis Pharmaceutical Co. Ltd., and Chugai Pharmaceutical Co. Ltd. ST has received speaker fees from Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Kyowa Kirin Co., Ltd., and Takeda Pharmaceutical Co., Ltd. HO has received speaker fees from Mitsubishi Tanabe Pharma Corporation, Daiichi Sankyo Co., Nippon Boehringer Ingelheim Co., Eli Lilly Japan K.K., AstraZeneca K.K., Ono Pharmaceutical Co. Ltd., Kyowa Kirin Co. Ltd., Novartis Pharmaceutical Co. Ltd., Torii Pharmaceutical Co. Ltd., Otsuka Pharmaceutical Co. Ltd., and Bayer Pharmaceutical Co. Ltd., and unrestricted research grants from Ono Pharmaceutical Co. Ltd., Kyowa Kirin Co. Ltd., Torii Pharmaceutical Co. Ltd., Chugai Pharmaceutical Co. Ltd., and Bayer Pharmaceutical Co. Ltd., and research funding from Kyowa Kirin Co. Ltd., Torii Pharmaceutical Co. Ltd., Kissei Pharmaceutical Co. Ltd., Chugai Pharmaceutical Co. Ltd., and Bayer Pharmaceutical Co. Ltd. ME has received speaker fees from Novo Nordisk Pharma Ltd., Nippon Boehringer Ingelheim Co., Sumitomo Pharma Co. Ltd., Sanofi K.K., Kyowa Kirin Co. Ltd., AstraZeneca K.K., and Ono Pharmaceutical Co. Ltd., and unrestricted research grants from Sumitomo Pharma Co. Ltd., Nippon Boehringer Ingelheim Co., Eisai Co. Ltd., Kyowa Kirin Co. Ltd., Mitsubishi Tanabe Pharma Corporation, Chugai Pharmaceutical Co. Ltd, and Bayer Pharmaceutical Co. Ltd. and research funding from Mitsubishi Tanabe Pharma Corporation and Kyowa Kirin Co. Ltd.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

###

About OMU
Established in Osaka as one of the largest public universities in Japan, Osaka Metropolitan University is committed to shaping the future of society through “Convergence of Knowledge” and the promotion of world-class research. For more research news, visit https://www.omu.ac.jp/en/ and follow us on social media: X, Facebook, Instagram, LinkedIn.
https://www.omu.ac.jp/en
Journal: Frontiers in Endocrinology
Title: Effects of canagliflozin on kidney oxygenation evaluated using blood oxygenation level-dependent MRI in patients with type 2 diabetes
DOI: 10.3389/fendo.2024.1451671
Author(s): Katsuhito Mori, Tsutomu Inoue, Yuri Machiba, Hideki Uedono, Shinya Nakatani, Masahiro Ishikawa, Satsuki Taniuchi, Yutaka Katayama, Akira Yamamoto, Naoki Kobayashi, Eito Kozawa, Taro Shimono, Yukio Miki, Hirokazu Okada, Masanori Emoto
Publication date: 30 August 2024
URL: https://doi.org/10.3389/fendo.2024.1451671
Attached files
  • BOLD MRI focusing on the kidneys: More red areas in the kidney indicate higher oxygen levels. Credit: Osaka Metropolitan University
18/11/2024 Osaka Metropolitan University
Regions: Asia, Japan
Keywords: Health, Medical, People in health research, Well being, Business, Medical & pharmaceutical

Disclaimer: AlphaGalileo is not responsible for the accuracy of news releases posted to AlphaGalileo by contributing institutions or for the use of any information through the AlphaGalileo system.

Testimonials

For well over a decade, in my capacity as a researcher, broadcaster, and producer, I have relied heavily on Alphagalileo.
All of my work trips have been planned around stories that I've found on this site.
The under embargo section allows us to plan ahead and the news releases enable us to find key experts.
Going through the tailored daily updates is the best way to start the day. It's such a critical service for me and many of my colleagues.
Koula Bouloukos, Senior manager, Editorial & Production Underknown
We have used AlphaGalileo since its foundation but frankly we need it more than ever now to ensure our research news is heard across Europe, Asia and North America. As one of the UK’s leading research universities we want to continue to work with other outstanding researchers in Europe. AlphaGalileo helps us to continue to bring our research story to them and the rest of the world.
Peter Dunn, Director of Press and Media Relations at the University of Warwick
AlphaGalileo has helped us more than double our reach at SciDev.Net. The service has enabled our journalists around the world to reach the mainstream media with articles about the impact of science on people in low- and middle-income countries, leading to big increases in the number of SciDev.Net articles that have been republished.
Ben Deighton, SciDevNet

We Work Closely With...

  • BBC
  • The Times
  • National Geographic
  • The University of Edinburgh
  • University of Cambridge
  • iesResearch
Copyright 2024 by AlphaGalileo Terms Of Use Privacy Statement